Please provide your email address to receive an email when new articles are posted on . BARCELONA, Spain — Adopting specific treatment regimens, reducing patient and staff travel, and limiting the use ...

Please provide your email address to receive an email when new articles are posted on . There are more options available than just the standard methods. Choices need to be made for every step of the ...

CHICAGO — Topical antibiotic prophylaxis is completely unnecessary in association with intravitreal injections, according to findings from more than 15,000 injections by a single surgeon who presented ...

Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...

STOCKHOLM — Current treatments for age-related macular degeneration (AMD) have proven effective and safe. However, these lifelong therapies involve frequent ocular injections. "It can be ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies ...

STOCKHOLM -- Two VEGF-targeting gene therapies for neovascular age-related macular degeneration (nAMD) substantially reduced treatment burden while preserving visual acuity, according to results ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ...

Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) Safety data were ...